Bolt Biotherapeutics (BOLT) stock price, revenue, and financials
Bolt Biotherapeutics market cap is $60.8 m, and annual revenue was $215 k in FY 2019
$1.7
$60.8 M
BOLT Mkt cap, 23-May-2022Bolt Biotherapeutics Net income (Q1, 2021)-24.5 M
Bolt Biotherapeutics EBIT (Q1, 2021)-18.4 M
Bolt Biotherapeutics Cash, 31-Mar-202195.5 M
Bolt Biotherapeutics EV-24 M
Bolt Biotherapeutics Income Statement
Annual
Bolt Biotherapeutics Balance Sheet
Annual
| USD | FY, 2018 | FY, 2019 |
|---|---|---|
Cash | 13.6m | 34.8m |
Prepaid Expenses | 466.0k | 1.1m |
Current Assets | 14.1m | 35.9m |
PP&E | 1.4m | 1.4m |
Total Assets | 16.0m | 48.4m |
Accounts Payable | 892.0k | 2.1m |
Short-term debt | 40.0k | 3.1m |
Current Liabilities | 2.8m | 8.7m |
Long-term debt | 7.1m | |
Total Debt | 40.0k | 10.2m |
Total Liabilities | 3.6m | 16.8m |
Preferred Stock | 28.4m | 77.5m |
Additional Paid-in Capital | 1.2m | 1.8m |
Retained Earnings | (17.2m) | (47.7m) |
Total Equity | (15.9m) | (45.8m) |
Debt to Equity Ratio | 0 x | -0.2 x |
Debt to Assets Ratio | 0 x | 0.2 x |
Financial Leverage | -1 x | -1.1 x |
Quarterly
| USD | Q3, 2020 | Q1, 2021 |
|---|---|---|
Cash | 17.8m | 95.5m |
Prepaid Expenses | 1.9m | 4.5m |
Current Assets | 39.7m | 271.2m |
PP&E | 4.2m | 3.9m |
Total Assets | 61.7m | 324.6m |
Accounts Payable | 3.4m | 2.9m |
Short-term debt | 1.3m | 1.6m |
Current Liabilities | 9.9m | 12.0m |
Long-term debt | 9.7m | 9.1m |
Total Debt | 11.0m | 10.7m |
Total Liabilities | 31.0m | 21.4m |
Common Stock | 36.3m | |
Preferred Stock | 105.3m | |
Additional Paid-in Capital | 2.8m | 436.2m |
Retained Earnings | (77.4m) | (132.9m) |
Total Equity | (74.6m) | 303.2m |
Debt to Equity Ratio | -0.1 x | |
Debt to Assets Ratio | 0.2 x | |
Financial Leverage | -0.8 x | 1.1 x |
Bolt Biotherapeutics Cash Flow
Annual
| USD | FY, 2018 | FY, 2019 |
|---|---|---|
Net Income | (11.6m) | (30.5m) |
Depreciation and Amortization | 302.0k | 335.0k |
Accounts Payable | 1.3m | 2.1m |
Cash From Operating Activities | (9.9m) | (26.3m) |
Purchases of PP&E | (290.0k) | (508.0k) |
Cash From Investing Activities | (290.0k) | (508.0k) |
Long-term Borrowings | (39.0k) | (40.0k) |
Cash From Financing Activities | 19.1m | 48.6m |
Net Change in Cash | 8.9m | 21.8m |
Interest Paid | 4.0k |
Quarterly
| USD | Q3, 2019 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|
Net Income | (21.1m) | (29.7m) | (24.5m) |
Depreciation and Amortization | 239.0k | 390.0k | 272.0k |
Accounts Payable | 365.0k | (221.0k) | (88.0k) |
Cash From Operating Activities | (20.1m) | (34.4m) | (16.6m) |
Purchases of PP&E | (441.0k) | (2.4m) | (58.0k) |
Cash From Investing Activities | (441.0k) | (22.3m) | (190.5m) |
Long-term Borrowings | (40.0k) | ||
Cash From Financing Activities | 48.6m | 40.7m | 297.0m |
Net Change in Cash | 28.1m | (16.1m) | 89.9m |
Bolt Biotherapeutics Ratios
| USD | FY, 2018 |
|---|---|
Financial Leverage | -1 x |
